デフォルト表紙
市場調査レポート
商品コード
1589465

糖尿病網膜症市場:タイプ別、管理別-2025-2030年の世界予測

Diabetic Retinopathy Market by Type (Non-proliferative DR, Proliferative DR), Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery) - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 192 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
糖尿病網膜症市場:タイプ別、管理別-2025-2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病網膜症市場は、2023年に3億7,638万米ドルと評価され、2024年には4億4,148万米ドルに達すると予測され、CAGR 17.69%で成長し、2030年には11億7,720万米ドルに達すると予測されています。

糖尿病網膜症(DR)は、網膜血管に影響を及ぼし、視力障害や失明につながる糖尿病誘発性の眼疾患です。この市場の分析範囲には、DRの管理または治療を目的とした現在の診断技術、医薬品治療、レーザー治療、予防治療法が含まれます。効率的なDR管理の必要性は、世界の糖尿病人口の増加と糖尿病関連合併症の発生率の増加から生じています。早期発見と早期管理は、深刻な視力低下を防ぐ上で非常に重要であり、眼科クリニック、病院、外来手術センター、眼科専門病棟など、アプリケーションの選択肢が豊富な分野となっています。主な市場促進要因としては、医療用画像処理技術の進歩、意識向上への取り組み、糖尿病と目の健康への取り組みに対する政府の資金援助などが挙げられます。特筆すべきは、AI主導の診断ツールや遠隔医療ソリューションの開発が最新の潜在機会を提示していることです。企業は、スマートフォン用眼底カメラやウェアラブル・モニタリング・デバイスなどの革新的技術に投資することで利益を得ることができます。しかし、高度な診断機器の高額なコスト、熟練したヘルスケア専門家の不足、医療サービスへのアクセスが限られた地方への普及の課題などにより、市場の成長は限界に直面しています。さらに、規制上の課題や治療オプションの潜在的な副作用が市場拡大の妨げとなっています。このような課題にもかかわらず、低侵襲治療オプションの革新や、個々の患者に特有のDRの進行をターゲットとした個別化医療アプローチにはチャンスがあります。競争の激しい市場であるため、薬剤の製剤や診断技術に継続的なイノベーションが求められ、コスト効率とアクセシビリティが重視されます。テクノロジー企業や研究機関とのパートナーシップは、重要な洞察力を生み出し、ブレークスルーを促進し、企業をビジョンケア市場の最前線に位置づけることができます。全体として、技術の進歩と手頃な価格およびアクセシビリティのバランスをとることは、新興市場を獲得し、アンメット・ニーズに対応する上で極めて重要です。

主な市場の統計
基準年[2023] 3億7,638万米ドル
予測年[2024] 4億4,148万米ドル
予測年[2030] 11億7,720万米ドル
CAGR(%) 17.69%

市場力学:急速に進化する糖尿病網膜症市場の主要市場インサイトを公開

糖尿病網膜症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 世界の糖尿病有病率の上昇
    • 糖尿病の管理とケアに関する意識の高まり
    • 糖尿病管理を促進する政府の取り組み
  • 市場抑制要因
    • 熟練した眼科医の不足
  • 市場機会
    • 先進的な治療法や薬剤の継続的なイントロダクション
    • 糖尿病黄斑浮腫治療のための併用療法の出現
  • 市場の課題
    • 糖尿病網膜症治療薬の承認に時間がかかること

ポーターの5つの力:糖尿病網膜症市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:糖尿病網膜症市場における外部からの影響の把握

外部マクロ環境要因は、糖尿病網膜症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析糖尿病網膜症市場における競合情勢の把握

糖尿病網膜症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス糖尿病網膜症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、糖尿病網膜症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨糖尿病網膜症市場における成功への道筋を描く

糖尿病網膜症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界的に糖尿病の罹患率が上昇
      • 糖尿病の管理とケアに関する意識の向上
      • 糖尿病管理を促進する政府の取り組み
    • 抑制要因
      • 熟練した眼科医の不足
    • 機会
      • 先進的な糖尿病網膜症治療法や薬剤の継続的なイントロダクション
      • 糖尿病黄斑浮腫の治療における複合療法の出現
    • 課題
      • 糖尿病網膜症医薬品の承認プロセスに時間がかかる
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 糖尿病網膜症市場:タイプ別

  • 非増殖性DR
  • 増殖性DR

第7章 糖尿病網膜症市場経営陣別

  • 抗VEGF療法
  • 眼内ステロイド注射
  • レーザー手術
  • 硝子体切除術

第8章 南北アメリカの糖尿病網膜症市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の糖尿病網膜症市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの糖尿病網膜症市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • BCN PEPTIDES, S.A.U.
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Kowa Company, Ltd.
  • Novartis AG
  • Opthea Limited
  • Oxurion NV
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sirnaomics Inc.
図表

LIST OF FIGURES

  • FIGURE 1. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC RETINOPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC RETINOPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY INTRAOCULAR STEROID INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 101. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-742BD517D2EC

The Diabetic Retinopathy Market was valued at USD 376.38 million in 2023, expected to reach USD 441.48 million in 2024, and is projected to grow at a CAGR of 17.69%, to USD 1,177.20 million by 2030.

Diabetic Retinopathy (DR) is a diabetes-induced eye condition that affects the retinal blood vessels and can lead to vision impairment and blindness. The scope of analysis within this market includes current diagnostic technologies, pharmaceutical treatments, laser therapies, and preventive care methods aimed at managing or treating DR. The necessity for efficient DR management arises from the growing global diabetic population and the increasing incidence of diabetes-related complications. Early detection and management are critical in preventing severe vision loss, making this an area rich with application options across eye care clinics, hospitals, outpatient surgical centers, and specialized ophthalmology wards. Key market growth drivers include advancements in medical imaging technologies, heightened awareness initiatives, and government funding for diabetes and eye health initiatives. Notably, the development of AI-driven diagnostic tools and telemedicine solutions presents the latest potential opportunities. Companies can benefit by investing in innovative technologies such as smartphone fundus cameras and wearable monitoring devices. However, market growth faces limitations driven by high costs of advanced diagnostic devices, lack of skilled healthcare professionals, and challenges in reaching rural areas with limited access to healthcare services. Furthermore, the market's expansion is hindered by regulatory challenges and potential side effects of treatment options. Despite these challenges, there are opportunities in the innovation of minimally invasive treatment options and personalized medicine approaches, targeting the unique progression of DR in individual patients. The market's competitive nature demands continuous innovation in drug formulations and diagnostic techniques, emphasizing cost-efficiency and accessibility. Fostering partnerships with technology firms and research institutions can generate significant insights and foster breakthroughs, thus positioning companies at the forefront of the vision care market. Overall, balancing technological advancements with affordability and accessibility will be crucial in capturing emerging markets and addressing the substantial unmet needs in diabetic retinopathy care.

KEY MARKET STATISTICS
Base Year [2023] USD 376.38 million
Estimated Year [2024] USD 441.48 million
Forecast Year [2030] USD 1,177.20 million
CAGR (%) 17.69%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Retinopathy Market

The Diabetic Retinopathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diabetes globally
    • Increasing awareness associated with diabetic management and care
    • Government initiatives to promote the diabetes management
  • Market Restraints
    • Dearth of skilled ophthalmologists
  • Market Opportunities
    • Ongoing introduction of advanced diabetic retinopathy treatments and drugs
    • Emergence of combine therapies for treatment of diabetic macular edema
  • Market Challenges
    • Time consuming approval process for diabetic retinopathy drugs

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Retinopathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Retinopathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Retinopathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Retinopathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Retinopathy Market

A detailed market share analysis in the Diabetic Retinopathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Retinopathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Retinopathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Retinopathy Market

A strategic analysis of the Diabetic Retinopathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Retinopathy Market, highlighting leading vendors and their innovative profiles. These include Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Bayer AG, BCN PEPTIDES, S.A.U., F. Hoffmann-La Roche AG, Kodiak Sciences Inc., Kowa Company, Ltd., Novartis AG, Opthea Limited, Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sirnaomics Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetic Retinopathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-proliferative DR and Proliferative DR.
  • Based on Management, market is studied across Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetes globally
      • 5.1.1.2. Increasing awareness associated with diabetic management and care
      • 5.1.1.3. Government initiatives to promote the diabetes management
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of skilled ophthalmologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing introduction of advanced diabetic retinopathy treatments and drugs
      • 5.1.3.2. Emergence of combine therapies for treatment of diabetic macular edema
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming approval process for diabetic retinopathy drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Retinopathy Market, by Type

  • 6.1. Introduction
  • 6.2. Non-proliferative DR
  • 6.3. Proliferative DR

7. Diabetic Retinopathy Market, by Management

  • 7.1. Introduction
  • 7.2. Anti-VEGF Therapy
  • 7.3. Intraocular Steroid Injection
  • 7.4. Laser Surgery
  • 7.5. Vitrectomy

8. Americas Diabetic Retinopathy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Retinopathy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Retinopathy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alimera Sciences, Inc.
  • 2. Allergan PLC
  • 3. Ampio Pharmaceuticals, Inc.
  • 4. Bausch & Lomb Incorporated
  • 5. Bayer AG
  • 6. BCN PEPTIDES, S.A.U.
  • 7. F. Hoffmann-La Roche AG
  • 8. Kodiak Sciences Inc.
  • 9. Kowa Company, Ltd.
  • 10. Novartis AG
  • 11. Opthea Limited
  • 12. Oxurion NV
  • 13. Pfizer Inc.
  • 14. Regeneron Pharmaceuticals Inc.
  • 15. Sirnaomics Inc.